NBTX
Nanobiotix S.A. (NASDAQ)
Healthcare — Biotechnology
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Price History
Fundamentals
| Market Cap | $2.01B |
| P/E Ratio (TTM) | - |
| Forward P/E | 511.58 |
| EPS (TTM) | $-0.57 |
| Dividend Yield | - |
| Profit Margin | -73.52% |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $43.64 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 70.0 |
| Beta | 0.59 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $57.14 |
| 52-Week Low | $4.79 |
| 50-Day Avg | $38.60 |
| 200-Day Avg | $27.58 |
| Avg Volume | 79.2K |
| Volume | 77.2K |
Performance Analysis
BULLISHNBTX shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:22 UTC
Back to Screener Export Report